Filing Details
- Accession Number:
- 0000899243-17-023137
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-10-02 16:40:07
- Reporting Period:
- 2017-10-02
- Accepted Time:
- 2017-10-02 16:40:07
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1654151 | Deciphera Pharmaceuticals Inc. | DCPH | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1547100 | Liam Ratcliffe | C/O Deciphera Pharmaceuticals, Inc. 500 Totten Pond Road Waltham MA 02451 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-10-02 | 839,110 | $0.00 | 839,110 | No | 4 | C | Indirect | See Footnote |
Common Stock | Acquisiton | 2017-10-02 | 1,118,722 | $0.00 | 1,957,832 | No | 4 | C | Indirect | See Footnote |
Common Stock | Acquisiton | 2017-10-02 | 279,703 | $0.00 | 279,703 | No | 4 | C | Indirect | See Footnote |
Common Stock | Acquisiton | 2017-10-02 | 1,118,722 | $0.00 | 1,398,425 | No | 4 | C | Indirect | See Footnote |
Common Stock | Acquisiton | 2017-10-02 | 372,883 | $0.00 | 1,771,308 | No | 4 | C | Indirect | See Footnote |
Common Stock | Acquisiton | 2017-10-02 | 375,000 | $17.00 | 2,146,308 | No | 4 | P | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See Footnote |
No | 4 | C | Indirect | See Footnote |
No | 4 | C | Indirect | See Footnote |
No | 4 | C | Indirect | See Footnote |
No | 4 | C | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series B-1 Preferred Stock | Disposition | 2017-10-02 | 148,515 | $0.00 | 839,110 | $0.00 |
Common Stock | Series B-2 Preferred Stock | Disposition | 2017-10-02 | 198,004 | $0.00 | 1,118,722 | $0.00 |
Common Stock | Series B-1 Preferred Stock | Disposition | 2017-10-02 | 49,505 | $0.00 | 279,703 | $0.00 |
Common Stock | Series B-2 Preferred Stock | Disposition | 2017-10-02 | 198,004 | $0.00 | 1,118,722 | $0.00 |
Common Stock | Series C Preferred Stock | Disposition | 2017-10-02 | 65,997 | $0.00 | 372,883 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into 5.65 shares of common stock of the Issuer.
- The reportable securities are owned directly by New Leaf Ventures III, L.P. ("NLV III"). New Leaf Venture Associates III, L.P. ("NLV Associates III") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. ("NLV Management III") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. ("NLVP") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- (Continuation from footnote 2) Each of the Reporting Person, Jeani Delagardelle, Ronald M. Hunt and Vijay K. Lathi (each, a "Member" and collectively, the "Members") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. ("Biopharma I"). New Leaf BPO Associates I, L.P. ("NLBA I") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- (Continuation from footnote 4) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.